143327-63-3

Upstream product

• 82362-50-3 4-(4-chlorophenyl)-1-(1H-imidazol-1-yl)-2-butanone 
• 23735-43-5 (S)-1-O-tosyl-2,3-O-isopropylideneglycerol 
• 67085-11-4 1-[2-hydroxy-4-(4-chlorophenyl)-n-butyl]imidazole 

Downstream Products

• 882004-55-9 (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)-methyl]-4-methyl-1,3-dioxalane 
• 1092853-02-5 (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 884381-82-2 (2R,4S)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4-[(phenylsulfanyl)methyl]-1,3-dioxolane 
• 884381-88-8 (2R,4S)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4-[(methylthio)methyl]-1,3-dioxolane 
• 1093058-51-5 1-{2-[2-(4-chlorophenyl)ethyl]-4-thiocyanatomethyl-[1,3]dioxolan-2-ylmethyl}-1H-imidazole 
• 1093058-32-2 (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4-(phenoxymethyl)-1,3-dioxolane 
• 884381-86-6 (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-4-(hydroxymethyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 1093058-31-1 (2R,4R)-4-(azidomethyl)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 1092851-91-6 (2R,4S)-4-(chloromethyl)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 884381-91-3 (2R,4S)-2-[2-(4-chlorophenyl)ethyl]-4-(fluoromethyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 1093058-53-7 (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4-(methoxymethyl)-1,3-dioxolane 
• 1092851-75-6 (2R,4S)-2-[2-(4-chlorophenyl)ethyl]-4-[(cyclohexylsulfanyl)methyl]-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 1156455-40-1 (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-4-[(4-fluorophenoxy)methyl]-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 
• 1093058-21-9 (2R,4S)-2-[2-(4-chlorophenyl)ethyl]-4-[(4-fluorophenyl-sulfanyl)methyl]-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane 

Relevant academic research and scientific papers

HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM

Disclosed are compounds of the general formula (1): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors

Several analogues based on the lead structure of azalanstat were synthesized and evaluated as novel inhibitors of heme oxygenase (HO). A number of these compounds, which are structurally distinct from metalloporphyrin HO inhibitors, were found to be selec